Aldevron has added GMP gene synthesis to its array of services. This expanded capability will be used primarily to support Aldevron’s clients who require rapid GMP gene synthesis for novel cancer treatments based on neoantigens. The company noted the service is not suited for routine, research-grade synthesis, for which Aldevron will continue using outside providers.
Aldevron and Odylia Form Partnership for Gene Therapy Treatments of Ultra-rare Diseases
Aldevron and Odylia, a nonprofit organization working to develop treatments for ultra-rare ocular diseases using gene therapy, have entered into an agreement in which Aldevron is a member of Odylia.
Aldevron announces ready-to-use helper plasmid for AAV manufacturing
New plasmid to reduce cost and timeline for gene therapy manufacturing
Aldevron, the world’s leading contract plasmid manufacturing organization, has announced the immediate availability of an off-the-shelf version of pXX6-80, a common adeno-associated virus (AAV) helper plasmid. The plasmid is designed to reduce the cost of AAV manufacturing and subsequent gene therapy applications, while helping Aldevron’s clients meet regulatory requirements.
Aldevron Expands Manufacturing Scale and Implements Single-use Fermentation Technology
Aldevron, a leading biotechnology contract manufacturing and development organization, is now using a 30-liter single-use fermentation system for manufacturing nucleic acids and proteins.
Aldevron Announces Growth Investment from TA Associates
(Fargo, N.D. and Boston, Mass.), January 24, 2017 – Aldevron, a contract development and manufacturing organization specializing in the production of plasmid DNA, proteins and antibodies, today announced it has received a growth investment from TA Associates, a leading global growth private equity firm. Aldevron’s management retains a significant portion of ownership in the company and will continue to run the company. Financial terms of the transaction were not disclosed.
Founded in 1998, Aldevron manufactures biologics for research, clinical and diagnostic applications. The company’s products are used to manufacture novel treatments for a wide range of indications, including cancer, infectious disease, pediatric disorders and rare diseases. Aldevron’s custom products are used extensively in the fields of gene therapy and gene editing. The company is headquartered in Fargo, North Dakota, and has additional facilities in Madison, Wisconsin, and Freiburg, Germany.